Literature DB >> 19147730

Specific determination of beta-galactocerebrosidase activity via competitive inhibition of beta-galactosidase.

Sabata Martino1, Roberto Tiribuzi, Andrea Tortori, Daniele Conti, Ilaria Visigalli, Annalisa Lattanzi, Alessandra Biffi, Angela Gritti, Aldo Orlacchio.   

Abstract

BACKGROUND: The determination of cellular beta-galactocerebrosidase activity is an established procedure to diagnose Krabbe disease and monitor the efficacy of gene/stem cell-based therapeutic approaches aimed at restoring defective enzymatic activity in patients or disease models. Current biochemical assays for beta-galactocerebrosidase show high specificity but generally require large protein amounts from scanty sources such as hematopoietic or neural stem cells. We developed a novel assay based on the hypothesis that specific measurements of beta-galactocerebrosidase activity can be performed following complete inhibition of beta-galactosidase activity.
METHODS: We performed the assay using 2-7.5 microg of sample proteins with the artificial fluorogenic substrate 4-methylumbelliferone-beta-galactopyranoside (1.5 mmol/L) resuspended in 0.1/0.2 mol/L citrate/phosphate buffer, pH 4.0, and AgNO(3). Reactions were incubated for 30 min at 37 degrees C. Fluorescence of liberated 4-methylumbelliferone was measured on a spectrofluorometer (lambda(ex) 360 nm, lambda(em) 446 nm).
RESULTS: AgNO(3) was a competitive inhibitor of beta-galactosidase [inhibition constant (K(i)) = 0.12 micromol/L] and completely inhibited beta-galactosidase activity when used at a concentration of 11 micromol/L. Under this condition, the beta-galactocerebrosidase activity was preserved and could be specifically and accurately measured. The assay can detect beta-galactocerebrosidase activity in as little as 2 microg cell protein extract or 7.5 microg tissue. Assay validation was performed using (a) brain tissues from wild-type and twitcher mice and (b) murine GALC(-/-) hematopoietic stem cells and neural precursor cells transduced by GALC-lentiviral vectors.
CONCLUSIONS: The procedure is straightforward, rapid, and reproducible. Within a clinical context, our method unequivocally discriminated cells from healthy subjects and Krabbe patients and is therefore suitable for diagnostic applications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19147730     DOI: 10.1373/clinchem.2008.115873

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  19 in total

1.  Cell-based high-throughput screening identifies galactocerebrosidase enhancers as potential small-molecule therapies for Krabbe's disease.

Authors:  Dae Song Jang; Wenjuan Ye; Tian Guimei; Melani Solomon; Noel Southall; Xin Hu; Juan Marugan; Marc Ferrer; Gustavo H B Maegawa
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 2.  [Demyelinating disorders].

Authors:  T Weber; W Köhler
Journal:  Nervenarzt       Date:  2010-04       Impact factor: 1.214

3.  Missense mutation in mouse GALC mimics human gene defect and offers new insights into Krabbe disease.

Authors:  Gregory B Potter; Marta Santos; Muriel T Davisson; David H Rowitch; Dan L Marks; Ernesto R Bongarzone; Magdalena A Petryniak
Journal:  Hum Mol Genet       Date:  2013-04-24       Impact factor: 6.150

4.  The galactocerebrosidase enzyme contributes to the maintenance of a functional hematopoietic stem cell niche.

Authors:  Ilaria Visigalli; Silvia Ungari; Sabata Martino; Hyejung Park; Martina Cesani; Bernhard Gentner; Lucia Sergi Sergi; Aldo Orlacchio; Luigi Naldini; Alessandra Biffi
Journal:  Blood       Date:  2010-05-28       Impact factor: 22.113

5.  Neural stem cell gene therapy ameliorates pathology and function in a mouse model of globoid cell leukodystrophy.

Authors:  Margherita Neri; Alessandra Ricca; Ilaria di Girolamo; Beatriz Alcala'-Franco; Chiara Cavazzin; Aldo Orlacchio; Sabata Martino; Luigi Naldini; Angela Gritti
Journal:  Stem Cells       Date:  2011-10       Impact factor: 6.277

6.  Macrophages Expressing GALC Improve Peripheral Krabbe Disease by a Mechanism Independent of Cross-Correction.

Authors:  Nadav I Weinstock; Daesung Shin; Narayan Dhimal; Xinying Hong; Eric E Irons; Nicholas J Silvestri; Chelsey B Reed; Duc Nguyen; Oliver Sampson; Yung-Chih Cheng; Joseph T Y Lau; Ernesto R Bongarzone; Julia Kofler; Maria L Escolar; Michael H Gelb; Lawrence Wrabetz; M Laura Feltri
Journal:  Neuron       Date:  2020-05-05       Impact factor: 17.173

7.  Altered Trafficking and Processing of GALC Mutants Correlates with Globoid Cell Leukodystrophy Severity.

Authors:  Daesung Shin; M Laura Feltri; Lawrence Wrabetz
Journal:  J Neurosci       Date:  2016-02-10       Impact factor: 6.167

8.  Human iPSC-based neurodevelopmental models of globoid cell leukodystrophy uncover patient- and cell type-specific disease phenotypes.

Authors:  Elisabeth Mangiameli; Anna Cecchele; Francesco Morena; Francesca Sanvito; Vittoria Matafora; Angela Cattaneo; Lucrezia Della Volpe; Daniela Gnani; Marianna Paulis; Lucia Susani; Sabata Martino; Raffaella Di Micco; Angela Bachi; Angela Gritti
Journal:  Stem Cell Reports       Date:  2021-05-13       Impact factor: 7.765

9.  Combined gene/cell therapies provide long-term and pervasive rescue of multiple pathological symptoms in a murine model of globoid cell leukodystrophy.

Authors:  Alessandra Ricca; Nicole Rufo; Silvia Ungari; Francesco Morena; Sabata Martino; Wilem Kulik; Valeria Alberizzi; Alessandra Bolino; Francesca Bianchi; Ubaldo Del Carro; Alessandra Biffi; Angela Gritti
Journal:  Hum Mol Genet       Date:  2015-03-05       Impact factor: 6.150

10.  MicroRNAs and Molecular Mechanisms of Neurodegeneration.

Authors:  Ilaria Bicchi; Francesco Morena; Simona Montesano; Mario Polidoro; Sabata Martino
Journal:  Genes (Basel)       Date:  2013-05-29       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.